Novartis Pharma K.K. Files New Drug Application For Agent For Treating Bronchial Asthma
Tokyo, June 26, 2006 (JCN) - Novartis Pharma Japan announced on June 26 that it has filed a new drug application for Xolair for Subcutaneous Injection 150mg, its proprietary agent for treating bronchial asthma (BA), with the Ministry of Health, Labor and Welfare.